Professor Robin Shattock is the Head of Mucosal Infection and Immunity within the Department of Medicine at Imperial College London. Professor Shattock’s research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. This has led to the establishment of international collaborations aimed at preclinical identification, development and selection of HIV microbicide and vaccine candidates prior to formal clinical efficacy trials.
Professor Shattock oversees a portfolio of research that is supported by 26 members of staff including researchers, PhD students, clinical trial managers and project managers. Professor Shattock has published over 160 peer reviewed articles in this area and secured funding from the European Commission, Bill and Melinda Gates Foundation, Wellcome Trust, MRC and the NIH.
DNAVAC is funded by the Gates Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD). Prof Shattock’s group is responsible for the DNAVAC project (https://www.cavd.org/grantees/Pages/Grantee-Shattock.aspx) which aims to apply recent state of the art technological advances in DNA vaccination and immune monitoring, both at the single cell and molecular level, to enable detailed probing of developing vaccine induced antibody responses.
ADITEC (Advanced Immunisation Technologies: http://www.aditecproject.eu) is funded under the 7th Framework by the EU. ADITEC is a collaborative research programme with 42 partners from 13 EU countries that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Professor Shattock leads the Prime-boost workpackage for the consortium.
BioVacSafe (Biomarkers for enhanced vaccines immunosafety - http://www.biovacsafe.eu) is a 5 years project funded by EU Innovative Medicine initiative (IMI). BioVacSafe aims to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. It is a public private consortium of 19 partners involving three of Europe's leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO): http://www.biovacsafe.eu/#sthash.UN2RSrBe.dpuf. Professor Shattock leads the work package on preclinical models.
The EAVI2020 consortium, funded under H2020 by the EU, is led by Prof Shattock at Imperial College London, and brings together leading HIV researchers from 23 public organisations and biotech companies from across Europe, Australia, Canada and the USA, pooling their knowledge and expertise to develop novel candidate vaccines that can be taken through to human trials within five years. http://www.eavi2020.eu. In addition to coordinating the programme, Prof Shattock’s group is responsible for performing a range of Experimental Medicine clinical trials of promising new HIV candidates.
Follow us on Twitter @vaxresearch
et al., 2020, Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice, Nature Communications, Vol:11, ISSN:2041-1723
et al., 2020, Chemokine-adjuvanted plasmid DNA induces homing of antigen-specific and non-Antigen-specific B and T cells to the intestinal and genital mucosae, Journal of Immunology, ISSN:0022-1767
et al., 2019, The safety and immunogenicity of GTU (R) MultiHIV DNA vaccine delivered by transcutaneous and intramuscular injection with or without electroporation in HIV-1 positive subjects on suppressive ART, Frontiers in Immunology, Vol:10, ISSN:1664-3224, Pages:1-8
et al., 2019, Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion, Vaccine, Vol:37, ISSN:0264-410X, Pages:7501-7508
et al., 2019, Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial, Lancet Infectious Diseases, Vol:19, ISSN:1473-3099, Pages:1091-1100